7,12,13-Trihydroxydocosa-8,10,14,16,19-pentaenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7,12,13-Trihydroxydocosa-8,10,14,16,19-pentaenoic acid
• 英文别名: 7,12,13-trihydroxydocosa-8,10,14,16,19-pentaenoic acid
• 化学式: C₂₂H₃₄O₅
• 分子量: 378.5
• InChiKey: XFIHWRRFJFILNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in individual patients
  申请人：Queen Mary University of London

  公开号：US11531036B2

  公开（公告）日：2022-12-20

  A method, device, computer program and related immunoassay are disclosed for assessing the efficacy of a statin selected from, for example, selected from RvT1 (7,13,20-trihydroxy-8,10,14,16Z,18-docosapentaenoic acid), RvT2 (7,12,13-trihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), RvT3 (7,8,13-trihydroxy-9,11,14,16Z,19Z-docosapentaenoic acid) and RvT4 (7,13-dihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), for use in the treatment of an inflammatory condition in an individual patient, which comprises measuring the levels of at least one 13-series resolvin in biological samples obtained from the patient before and after administration of the statin, wherein an increase in the level of the resolvin after administration of the statin is indicative of efficacy of the statin. Also disclosed is a method of storing a biological sample to preserve lipid mediators in the sample comprising placing the sample in an organic solvent and storing the sample at a temperature of ≤−75° C.

  本发明公开了一种方法、装置、计算机程序和相关免疫测定，用于评估选自下列药物的他汀类药物的疗效，例如，选自 RvT1（7,13,20-三羟基-8,10,14,16Z、18-二十碳五烯酸）、RvT2（7,12,13-三羟基-8,10,14,16Z,19Z-二十碳五烯酸）、RvT3（7,8,13-三羟基-9,11,14,16Z,19Z-二十碳五烯酸）和 RvT4（7,13-二羟基-8,10,14,16Z、其中包括在服用他汀类药物之前和之后测量从患者处获得的生物样本中至少一种 13 系列溶血素的水平，其中服用他汀类药物后溶血素水平的增加表明他汀类药物的疗效。还公开了一种储存生物样本以保存样本中脂质介质的方法，包括将样本置于有机溶剂中，并将样本储存在温度≤-75℃的环境中。
• METHOD AND APPARATUS FOR DETERMINING THE EFFICACY OF STATINS FOR TREATING INFLAMMATORY DISEASES IN INDIVIDUAL PATIENTS
  申请人：Queen Mary University of London

  公开号：EP3635411A1

  公开（公告）日：2020-04-15
• [EN] METHOD AND APPARATUS FOR DETERMINING THE EFFICACY OF STATINS FOR TREATING INFLAMMATORY DISEASES IN INDIVIDUAL PATIENTS<br/>[FR] PROCÉDÉ ET APPAREIL DE DÉTERMINATION DE L'EFFICACITÉ DE STATINES DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES CHEZ DES PATIENTS INDIVIDUELS
  申请人：UNIV LONDON QUEEN MARY

  公开号：WO2018197650A1

  公开（公告）日：2018-11-01

  A method, device, computer program and related immunoassay are disclosed for assessing the efficacy of a statin selected from, for example, selected from RvT1 (7,13,20-trihydroxy-8,10,14,16Z,18-docosapentaenoic acid), RvT2 (7,12,13-trihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), RvT3 (7,8,13-trihydroxy-9,11,14,16Z,19Z-docosapentaenoic acid) and RvT4 (7,13-dihydroxy-8,10,14,16Z,19Z-docosapentaenoic acid), for use in the treatment of an inflammatory condition in an individual patient, which comprises measuring the levels of at least one 13-series resolvin in biological samples obtained from the patient before and after administration of the statin, wherein an increase in the level of the resolvin after administration of the statin is indicative of efficacy of the statin. Also disclosed is a method of storing a biological sample to preserve lipid mediators in the sample comprising placing the sample in an organic solvent and storing the sample at a temperature of ≤ -75° C.